Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
about
Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep.The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.Ethics review in compassionate useClinical use of nintedanib in patients with idiopathic pulmonary fibrosis.Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.Nintedanib for the treatment of idiopathic pulmonary fibrosis.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Nintedanib for Idiopathic Pulmonary Fibrosis.Idiopathic pulmonary fibrosis: pathogenesis and management.Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.Idiopathic Pulmonary Fibrosis (IPF): An OverviewEfficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosisSafety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practiceNintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
P2860
Q39329860-816AA06D-5FA0-4E52-92F2-01E161977024Q39344375-F34ABF3F-F6FF-4EBF-A7DB-A8415039952BQ39452672-3615064E-044E-4E74-A28B-8457E9C66E18Q41151927-1AA90FA2-A3A1-4C6E-B9C8-E5BD2CCABD29Q47161826-2810AC55-ABFC-4B1C-921E-0DB640E65595Q47361127-839BF545-F034-4EB0-9FB6-537B498E92B6Q47658514-D29D3574-3C5F-420F-BF5A-9F74ECF1ADBBQ47791471-13DB4570-7B25-4373-83AC-EEE2B25BC229Q47826077-CFB8DD47-05DC-4EB9-9FEF-19410D5FCADFQ50326794-8C10526B-7992-40A7-A9C8-FFA33212A912Q51410548-DC8D9AB6-0EB0-4283-9B5A-9024A2A522BFQ57170607-9D5407FD-CB4B-4B53-955E-2F2283DFE460Q57811298-ABD1E7AF-2AD5-465C-855C-71EF62E2B063Q58587321-4E81D0EE-D522-48F1-B795-D0A94F7AF86CQ58698965-289AB860-528B-4BCF-863D-D4A5D77FB774
P2860
Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@en
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@nl
type
label
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@en
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@nl
prefLabel
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@en
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@nl
P2093
P356
P1433
P1476
Insights from the German Compa ...... Idiopathic Pulmonary Fibrosis.
@en
P2093
Antje Prasse
Claus Keller
Claus Neurohr
Francesco Bonella
German Nintedanib Compassionate Use Consortium
Joachim Müller-Quernheim
Katrin Milger
Lars Hagmeyer
Martin J Kohlhaeufl
Michael Kreuter
P304
P356
10.1159/000448288
P577
2016-08-20T00:00:00Z